Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial

Cutaneous warts comprise an extremely common condition caused by infection with the human papillomavirus (HPV). Although most verrucae will disappear spontaneously, many patients do seek treatment. Current wart treatments do not target the cause of the lesion directly, resulting in variable treatmen...

Full description

Bibliographic Details
Main Authors: Nina Redzic, Ina Benoy, Davy Vanden Broeck, Johannes.P. Bogers
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:Contemporary Clinical Trials Communications
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865420300181
id doaj-cc828b22061c47ce963df25c972966ba
record_format Article
spelling doaj-cc828b22061c47ce963df25c972966ba2020-11-25T02:13:41ZengElsevierContemporary Clinical Trials Communications2451-86542020-03-0117Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trialNina Redzic0Ina Benoy1Davy Vanden Broeck2Johannes.P. Bogers3AMBIOR, Laboratory for Cell Biology & Histology, University of Antwerp, Antwerp, Belgium; Laboratory of Molecular Pathology, AML, Antwerp, Belgium; Corresponding author. Campus Drie Eiken, Universiteitsplein 1, D.T.130, 2160, Wilrijk, Belgium.AMBIOR, Laboratory for Cell Biology & Histology, University of Antwerp, Antwerp, Belgium; Laboratory of Molecular Pathology, AML, Antwerp, Belgium; National Reference Centre for HPV, Brussels, BelgiumAMBIOR, Laboratory for Cell Biology & Histology, University of Antwerp, Antwerp, Belgium; Laboratory of Molecular Pathology, AML, Antwerp, Belgium; National Reference Centre for HPV, Brussels, Belgium; International Centre for Reproductive Health, Department of Obstetrics and Gynecology, Ghent University, Ghent, BelgiumAMBIOR, Laboratory for Cell Biology & Histology, University of Antwerp, Antwerp, Belgium; Laboratory of Molecular Pathology, AML, Antwerp, Belgium; National Reference Centre for HPV, Brussels, BelgiumCutaneous warts comprise an extremely common condition caused by infection with the human papillomavirus (HPV). Although most verrucae will disappear spontaneously, many patients do seek treatment. Current wart treatments do not target the cause of the lesion directly, resulting in variable treatment efficacies and high wart recurrence rates. AV2 is a broad-spectrum antiviral drug, that is capable of deactivating HPV. It is however not able to destruct the already infected cells, which raises the need for an additional ablative treatment i.e. salicylic acid (SA). Implementation of AV2-Salicylic acid (AV2-SA) combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.The primary aim of this study is to assess the efficacy of AV2-SA treatment versus standard SA treatment, by comparing cure and recurrence rates of cutaneous warts between the two treatment groups (at 12 weeks and six months after randomization). The second aim is to assess the safety and tolerability of AV2-SA therapy. The third aim is to identify subgroups of cutaneous warts that have favorable response to treatment, by comparing cure rates in an HPV genotype-specific manner.This randomized controlled trial will enroll 260 participants with cutaneous warts who will either receive the AV2-SA combination therapy or SA control treatment. Real time monitoring will be possible by daily photographs sent via WhatsApp™ (a messaging application) as well as online follow-up questionnaires administered on several occasions. HPV genotyping will be performed on swab self-samples. Keywords: Cutaneous warts, Antiviral drug, Study protocol, Clinical research, AV2-Salicylic acid combination therapy, HPV genotyping, Randomized controlled trial, Omnivirolhttp://www.sciencedirect.com/science/article/pii/S2451865420300181
collection DOAJ
language English
format Article
sources DOAJ
author Nina Redzic
Ina Benoy
Davy Vanden Broeck
Johannes.P. Bogers
spellingShingle Nina Redzic
Ina Benoy
Davy Vanden Broeck
Johannes.P. Bogers
Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial
Contemporary Clinical Trials Communications
author_facet Nina Redzic
Ina Benoy
Davy Vanden Broeck
Johannes.P. Bogers
author_sort Nina Redzic
title Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial
title_short Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial
title_full Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial
title_fullStr Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial
title_full_unstemmed Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial
title_sort efficacy of av2-salicylic acid combination therapy for cutaneous warts: study protocol for a single-center randomized controlled trial
publisher Elsevier
series Contemporary Clinical Trials Communications
issn 2451-8654
publishDate 2020-03-01
description Cutaneous warts comprise an extremely common condition caused by infection with the human papillomavirus (HPV). Although most verrucae will disappear spontaneously, many patients do seek treatment. Current wart treatments do not target the cause of the lesion directly, resulting in variable treatment efficacies and high wart recurrence rates. AV2 is a broad-spectrum antiviral drug, that is capable of deactivating HPV. It is however not able to destruct the already infected cells, which raises the need for an additional ablative treatment i.e. salicylic acid (SA). Implementation of AV2-Salicylic acid (AV2-SA) combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.The primary aim of this study is to assess the efficacy of AV2-SA treatment versus standard SA treatment, by comparing cure and recurrence rates of cutaneous warts between the two treatment groups (at 12 weeks and six months after randomization). The second aim is to assess the safety and tolerability of AV2-SA therapy. The third aim is to identify subgroups of cutaneous warts that have favorable response to treatment, by comparing cure rates in an HPV genotype-specific manner.This randomized controlled trial will enroll 260 participants with cutaneous warts who will either receive the AV2-SA combination therapy or SA control treatment. Real time monitoring will be possible by daily photographs sent via WhatsApp™ (a messaging application) as well as online follow-up questionnaires administered on several occasions. HPV genotyping will be performed on swab self-samples. Keywords: Cutaneous warts, Antiviral drug, Study protocol, Clinical research, AV2-Salicylic acid combination therapy, HPV genotyping, Randomized controlled trial, Omnivirol
url http://www.sciencedirect.com/science/article/pii/S2451865420300181
work_keys_str_mv AT ninaredzic efficacyofav2salicylicacidcombinationtherapyforcutaneouswartsstudyprotocolforasinglecenterrandomizedcontrolledtrial
AT inabenoy efficacyofav2salicylicacidcombinationtherapyforcutaneouswartsstudyprotocolforasinglecenterrandomizedcontrolledtrial
AT davyvandenbroeck efficacyofav2salicylicacidcombinationtherapyforcutaneouswartsstudyprotocolforasinglecenterrandomizedcontrolledtrial
AT johannespbogers efficacyofav2salicylicacidcombinationtherapyforcutaneouswartsstudyprotocolforasinglecenterrandomizedcontrolledtrial
_version_ 1724903698452185088